Landscapes / Companies
Furthest along
5 approved
6 in Phase 2
Drugs
15
in active trials · 48 in all
Trials
19 active
162 since 2021
Drugs15
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Amyloid-beta protofibril antibody |
Biogen |
Approved | 3 Dec 2026soonPhase 2 trial completes | ||
| Next date | 3 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Early Alzheimer's Disease, Preclinical Alzheimer's Disease and 2 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Merck & Co. |
Approved | 22 Mar 2027Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 22 Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Carcinoma, Renal Cell, Renal Cell Carcinoma and 14 more | ||||
| Open drug page | |||||
Eribulin mesylatenot checked |
Microtubule inhibitor |
Approved | 31 Mar 2027Phase 1/2 trial completes | ||
| Next date | 31 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumor, Solid Neoplasms | ||||
| Open drug page | |||||
JAK inhibitor |
Approved in Japan | 30 Nov 2027Phase 4 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 30 Nov 2027 · Phase 4 trial completes | ||||
| Also tested for | Ulcerative Colitis | ||||
| Open drug page | |||||
Donepezilnot checked |
Cholinesterase inhibitor |
Approved | 6 May 2030Phase 1 trial completes | ||
| Next date | 6 May 2030 · Phase 1 trial completes | ||||
| Also tested for | Alzheimers Disease | ||||
| Open drug page | |||||
— |
Phase 2 | 3 Dec 2026soonPhase 2 trial completes | |||
| Next date | 3 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Alzheimer's Disease | ||||
| Open drug page | |||||
— |
Phase 2 | 14 Feb 2027Phase 2 trial completes | |||
| Next date | 14 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Narcolepsy | ||||
| Open drug page | |||||
— |
Phase 1/2 | 31 Mar 2027Phase 1/2 trial completes | |||
| Next date | 31 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Colorectal Neoplasms, Advanced Neoplasms and 6 more | ||||
| Open drug page | |||||
E2007not checked |
— |
Phase 2 | 6 Apr 2027Phase 2 trial completes | ||
| Next date | 6 Apr 2027 · Phase 2 trial completes | ||||
| Also tested for | Pediatric Epileptic Syndrome, Partial-onset Seizures | ||||
| Open drug page | |||||
— |
Phase 2 | 5 Aug 2028Phase 2 trial completes | |||
| Next date | 5 Aug 2028 · Phase 2 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 1/2 | 8 Aug 2030Phase 1/2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 8 Aug 2030 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumor | ||||
| Open drug page | |||||
— |
Phase 1 | 22 Jul 2027Phase 1 trial completes | |||
| Next date | 22 Jul 2027 · Phase 1 trial completes | ||||
| Also tested for | Malaria | ||||
| Open drug page | |||||
Tasurgratinibnot checked |
Tyrosine kinase inhibitor |
Phase 1 | 31 Aug 2027Phase 1 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 31 Aug 2027 · Phase 1 trial completes | ||||
| Also tested for | Hepatic Impairment | ||||
| Open drug page | |||||
— |
Phase 1 | 6 May 2030Phase 1 trial completes | |||
| Next date | 6 May 2030 · Phase 1 trial completes | ||||
| Also tested for | Alzheimers Disease | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Receptors, Estrogen, Genes, Erbb-2 and 1 more | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- 33 other drugs
- SEC filings
- None: it does not file with the US SEC
- Registry names
- 5 names in ClinicalTrials.gov Eisai Inc.
Eisai Co., Ltd.
Eisai Limited
Eisai Korea Inc.
Eisai Pharmaceuticals India Pvt. Ltd - Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021